COLORECTAL CANCER: Overcoming resistance to anti-EGFR therapy — where do we stand?

    loading  Checking for direct PDF access through Ovid

Abstract

In the past few years, the mechanisms leading to an acquired resistance to anti-EGFR monoclonal antibodies became an important topic in metastatic colorectal cancer research. In this commentary, we briefly summarize the latest update to this field by Arena and colleagues, and discuss promising new drugs and treatment strategies that might lead to overcoming secondary resistance.

Related Topics

    loading  Loading Related Articles